Heron Therapeutics | HRTX - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
ALKERMES USD 20.89M 8.62M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amarin USD 3K 5K 2024-12
ANI Pharmaceuticals USD 4.41M 316K 2025-12
Anika Therapeutics 179.39M 556.84M 2026-03
Arrowhead Research USD 22.5M 811K 2025-12
Eisai JPY 1.55B 117M 2026-03
Esperion Therapeutics USD 22.64M 585K 2025-12
GlaxoSmithKline GBP 167M 21M 2026-03
Heron Therapeutics USD 600K 100K 2024-12
Insmed USD 20.08M 517K 2026-03
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
Merck USD 479M 67M 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Omeros USD 4.05M 5.16M 2024-09
Pacira USD 3.7M 193K 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Veracyte USD 2K 1000 2023-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12